News

HCT Tied to Long-Term Survival and Early Death in Certain Patients With MF

05/28/2020

Study findings suggest that there is a long-term survival advantage of allogeneic HCT in certain patients with MF, but at the expense of possible early death.

Study findings suggest that...

05/28/2020

Oncology

News

Hydroxyurea Use in Patients With PV Requires Active Monitoring, Management

04/17/2020

Active management is needed for patients with PV given hydroxyurea to maintain blood count control, with extra monitoring for signs and symptoms of hydroxyurea intolerance.

Active management is needed for...

04/17/2020

Oncology

News

FDA Approves Drug to Treat Anemia in Patients With MDS

04/07/2020

The FDA has approved luspatercept-aamt for the treatment of anemia in certain adults with MDS.

The FDA has approved...

04/07/2020

Oncology

News

Enasidenib Well-Tolerated, Active in Patients With IDH2-Mutated MDS

03/23/2020

Enasidenib was shown to be well-tolerated and clinically active in a study of patients with relapsed or refractory IDH2-mutated MDS.

Enasidenib was shown to be...

03/23/2020

Oncology

News

Risk for Vascular Complications Greatly Affects Life Expectancy in ET and PV

03/19/2020

The risk for vascular complications among patients with ET and PV are high, and these complications pose a considerable threat on life expectancy.

The risk for vascular...

03/19/2020

Oncology

News

Fludarabine–Treosulfan Conditioning Combo Improves Post-Transplant Outcomes in MDS

03/04/2020

Standard myeloablative conditioning before allo-HSCT is significantly inferior to conditioning with fludarabine and treosulfan in patients with MDS.

Standard myeloablative...

03/04/2020

Oncology

News

Long-Term Ropeginterferon Alfa-2b Safe, Effective for Polycythemia Vera

02/27/2020

Ropeginterferon alfa-2b induces high and durable hematologic and molecular responses and demonstrates improved responses over time over hydroxyurea in PV.

Ropeginterferon alfa-2b induces...

02/27/2020

Oncology

News

Researchers Identify Prognostic Factors in TP53-Mutated MDS

02/24/2020

A retrospective study finds karyotypic complexity and TP53 variant allele frequency can define prognostic subgroups in TP53-mutated MDS and TP53 VAF helps predict survival outcomes to treatment.

A retrospective study finds...

02/24/2020

Oncology

News

Long-Term Ruxolitinib Safe, Effective for Polycythemia Vera

02/12/2020

Long-term results from the RESPONSE trial show that ruxolitinib is a safe and effective therapy option for patients with PV resistant to or intolerant of hydroxyurea.

Long-term results from the...

02/12/2020

Oncology

News

Ruxolitinib Combo Therapy Reduces Symptom Burden in Patients With PV, MF

01/22/2020

In patients with PV and MF, ruxolitinib therapy plus low-dose PEG-IFNα2 improved cell counts and reduced symptom burden with acceptable toxicity.

In patients with PV and MF,...

01/22/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology